227 related articles for article (PubMed ID: 9499248)
41. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
[No Abstract] [Full Text] [Related]
42. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia.
Andréasson B; Swolin B; Kutti J
Eur J Haematol; 2000 Mar; 64(3):188-93. PubMed ID: 10997885
[TBL] [Abstract][Full Text] [Related]
43. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard.
Toh BT; Gregory SA; Knospe WH
Am J Hematol; 1988 May; 28(1):58-60. PubMed ID: 3369437
[TBL] [Abstract][Full Text] [Related]
44. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
45. [Efficacious treatment of a fatal blood disease: polycythemia vera].
Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
[No Abstract] [Full Text] [Related]
46. Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment.
Salmon-Ehr V; Grosieux C; Potron G; Kalis B
Dermatology; 1998; 196(2):274. PubMed ID: 9568428
[No Abstract] [Full Text] [Related]
47. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
[TBL] [Abstract][Full Text] [Related]
48. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
[No Abstract] [Full Text] [Related]
49. Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?
Hasselbalch HC; Silver RT
Expert Rev Hematol; 2015 Aug; 8(4):439-45. PubMed ID: 25996953
[TBL] [Abstract][Full Text] [Related]
50. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Albizua E; Gallardo M; Barrio S; Rapado I; Jimenez A; Ayala R; Rueda D; Sanchez-Espiridion B; Puigdecanet E; Espinet B; Florensa L; Besses C; Martinez-Lopez J
Ann Hematol; 2011 Aug; 90(8):939-46. PubMed ID: 21331593
[TBL] [Abstract][Full Text] [Related]
51. Essential thrombocythemia and aortic dissection,causal or incidental association?
Laktib N; Mahtat EM; Lahlafi Z; Mouine N; Asfalou I; Aghoutane N; Chaib A; Lakhal Z; Doghmi K; Benyass A
J Med Vasc; 2022 Feb; 47(1):39-42. PubMed ID: 35393092
[TBL] [Abstract][Full Text] [Related]
52. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
Karakantza M; Giannakoulas NC; Zikos P; Sakellaropoulos G; Kouraklis A; Aktypi A; Metallinos IC; Theodori E; Zoumbos NC; Maniatis A
Int J Hematol; 2004 Apr; 79(3):253-9. PubMed ID: 15168594
[TBL] [Abstract][Full Text] [Related]
53. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.
Gómez M; Guillem V; Pereira A; Ferrer-Marín F; Álvarez-Larrán A; Kerguelen A; Estrada N; Martínez-López J; Angona A; Amat P; Navarro B; Besses C; Hernández-Boluda JC
Eur J Haematol; 2016 Mar; 96(3):285-90. PubMed ID: 25996073
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyurea-induced fever and hepatitis.
Westerman DA; Schwarer A; Grigg AP
Aust N Z J Med; 1998 Oct; 28(5):657-9. PubMed ID: 9847957
[No Abstract] [Full Text] [Related]
55. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Fruchtman SM; Mack K; Kaplan ME; Peterson P; Berk PD; Wasserman LR
Semin Hematol; 1997 Jan; 34(1):17-23. PubMed ID: 9025158
[No Abstract] [Full Text] [Related]
56. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
57. Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide.
Angona A; Bellosillo B; Alvarez-Larrán A; Martínez-Avilés L; Camacho L; Pairet S; Fernández-Rodriguez MC; Ancochea A; Besses C
Leuk Res; 2013 Aug; 37(8):917-21. PubMed ID: 23597578
[TBL] [Abstract][Full Text] [Related]
58. Running interferon interference in treating PV/ET: meeting unmet needs.
Traxler EA; Hexner EO
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):463-468. PubMed ID: 34889420
[TBL] [Abstract][Full Text] [Related]
59. Procarbazine (Natulan) and busulfan in the treatment of polycythemia vera.
Penttilä O; Ikkala E
Ann Med Intern Fenn; 1968; 57(2):99-101. PubMed ID: 5706392
[No Abstract] [Full Text] [Related]
60. Novel oral anticoagulants in the management of polycythemia vera and essential thrombocythemia.
Karali V; Panayiotidis P
Cardiovasc Hematol Agents Med Chem; 2014; 12(1):26-8. PubMed ID: 25470150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
